Exclusivity Patents and exclusivity Drug Information Prescribing and other information DMFs Type 2 master files Databases Free access to database search 21 CFR FDA regulations for this API Federal Register FR search results for this API Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… Starlix (nateglinide) Tablets, Novartis NDA 21-204/S6 1020/03 10/27/03 10/27/03 Starlix (nateglinide) Tablets, 60 mg and 120 mg., Novartis NDA 21-204/S5 11/26/02 12/9/02 12/4/02 Starlix (nateglinide) Tablets, 60 mg and 120 mg. Novartis NDA 21-204 12/22/00 1/9/01 1/9/01 3/18/02 Starlix Indication: Provides for the use of Starlix as monotherapy, as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. In addition, it provides for the use of Starlix concomitantly with metformin to improve glycemic control. Risperdal Consta (risperidone) Long -Acting Injection, Johnson & Johnson Starlix (nateglinide) Tablets, Novartis Pharmaceuticals, Labeling Revision | Nateglinide Tablets, Par Pharma, Tentative Approval | Starlix (nateglinide) Tablets, Novartis Pharma, Labeling Revision Check the most up-to-date list of FDA Approvals.   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | FindingHealthOnline © 2008 Betterchem.com